VICAL INC Contracts & Agreements

Separation and Release Agreement, dated as of October 3, 2023, by and between Fresh Tracks Therapeutics, Inc. and Andrew D. Sklawer (Filed With SEC on October 10, 2023)

Consulting Agreement, dated as of October 3, 2023, by and between Fresh Tracks Therapeutics, Inc. and Yonder Partners, LLC (Filed With SEC on October 10, 2023)

Plan of Dissolution of Fresh Tracks Therapeutics, Inc (Filed With SEC on September 19, 2023)

Amendment No. 1 to Asset Purchase Agreement, dated as of July 21, 2023, by and among Fresh Tracks Therapeutics, Inc., Brickell Subsidiary, Inc., Botanix SB Inc., and Botanix... (Filed With SEC on July 21, 2023)

Second Amendment to Rights Agreement, dated as of July 21, 2023, by and among Fresh Tracks Therapeutics, Inc., Brickell Subsidiary, Inc., and Bodor Laboratories, Inc (Filed With SEC on July 21, 2023)

Letter Agreement, dated as of May 4, 2023, by and between Fresh Tracks Therapeutics, Inc. and BRE-BMR Flatiron VII LLC (f/k/a GPIF 5777 Flatiron LLC and BMC Properties, LLC) (Filed With SEC on May 10, 2023)

Description of the Registrants Securities Registered Pursuant to Section 12 of the Exchange Act (Filed With SEC on March 30, 2023)

Fifth Amendment to Lease Agreement, dated as of December 29, 2022, by and between Fresh Tracks Therapeutics, Inc. and BRE-BMR Flatiron VII LLC (f/k/a GPIF 5777 Flatiron LLC and... (Filed With SEC on March 30, 2023)

Form of Indemnification Agreement by and between the Company and its directors and executive officers (Filed With SEC on March 30, 2023)

Amended and Restated Employment Agreement by and between Fresh Tracks Therapeutics, Inc. and Brickell Subsidiary, Inc., on the one hand, and David R. McAvoy, on the other hand,... (Filed With SEC on March 30, 2023)

Fresh Tracks Therapeutics, Inc. Employee Stock Purchase Plan (Filed With SEC on March 30, 2023)

Amended and Restated Employment Agreement, dated as of February 21, 2023, between Fresh Tracks Therapeutics, Inc. and Brickell Subsidiary, Inc., on the one hand, and Andrew D.... (Filed With SEC on February 24, 2023)

Amended and Restated Employment Agreement, dated as of February 21, 2023, by and between Fresh Tracks Therapeutics, Inc. and Brickell Subsidiary, Inc., on the one hand, and Deepak... (Filed With SEC on February 24, 2023)

Form of Employee Retention Bonus Agreement (Filed With SEC on February 24, 2023)

Amended and Restated Offer of Employment, by and between Fresh Tracks Therapeutics, Inc. and Aaron Fox-Collis, effective as of January 1, 2023 (Filed With SEC on February 22, 2023)

Transition and Release Agreement, by and between Fresh Tracks Therapeutics, Inc. and Robert B. Brown, dated as of February 1, 2023 (Filed With SEC on February 7, 2023)

Consulting Agreement, by and between Fresh Tracks Therapeutics, Inc. and Dancing Bear Consulting, LLC, effective as of January 31, 2023 (Filed With SEC on January 27, 2023)

Fresh Tracks Therapeutics, Inc. 2020 Omnibus Long-Term Incentive Plan, as amended on May 17, 2022 (Filed With SEC on November 14, 2022)

Fresh Tracks Therapeutics, Inc. Employee Stock Purchase Plan (Filed With SEC on November 14, 2022)

Form of Restricted Stock Unit Award Agreement under the Fresh Tracks Therapeutics, Inc. 2020 Omnibus Long-Term Incentive Plan (Filed With SEC on November 14, 2022)

Form of Incentive Stock Option Award Agreement under the Fresh Tracks Therapeutics, Inc. 2020 Omnibus Long-Term Incentive Plan (Filed With SEC on November 14, 2022)

Form of Non-Qualified Stock Option Award Agreement under the Fresh Tracks Therapeutics, Inc. 2020 Omnibus Long-Term Incentive Plan (Filed With SEC on November 14, 2022)

Acknowledgment and Agreement Related to Asset Purchase Agreement and Amended and Restated License Agreement, dated as of November 10, 2022, by and among Fresh Tracks Therapeutics,... (Filed With SEC on November 14, 2022)

Amendment to Rights Agreement, dated as of November 10, 2022, by and among Fresh Tracks Therapeutics, Inc., Brickell Subsidiary, Inc. and Bodor Laboratories, Inc (Filed With SEC on November 14, 2022)

Subscription and Investment Representation Agreement, dated May 25, 2022, by and between Brickell Biotech, Inc. and the purchaser signatory thereto (Filed With SEC on May 25, 2022)

Brickell Biotech, Inc. Omnibus Long-Term Incentive Plan, as amended through May 17, 2022 (Filed With SEC on May 17, 2022)

Asset Purchase Agreement, dated as of May 3, 2022, by and among Brickell Biotech, Inc., Brickell Subsidiary, Inc., Botanix SB Inc., and Botanix Pharmaceuticals Limited (Filed With SEC on May 3, 2022)

Transition Services Agreement, dated as of (Filed With SEC on May 3, 2022)

Rights Agreement, dated as of May 3, 2022, by and among Brickell Biotech, Inc., Brickell Subsidiary, Inc., and Bodor Laboratories, Inc (Filed With SEC on May 3, 2022)

Description of the Registrants Securities Registered Pursuant to Section 12 of the Exchange Act (Filed With SEC on March 15, 2022)

Exclusive License Agreement, dated as of February 2, 2022, by and between Carna Biosciences, Inc. and Brickell Biotech, Inc (Filed With SEC on February 2, 2022)

Employment Agreement, dated August 26, 2021, by and between Brickell Biotech, Inc. and Monica Luchi (Filed With SEC on November 9, 2021)

License and Development Agreement, dated as of August 27, 2021, by and between Voronoi Inc. and Brickell Biotech, Inc (Filed With SEC on September 1, 2021)

Fourth Amendment to Lease Agreement, dated as of June 17, 2021, by and between Brickell Biotech, Inc. and GPIF 5777 Flatiron LLC (f/k/a BMC Properties, LLC) (Filed With SEC on August 12, 2021)

Brickell-Kaken Amendment to Clinical Supply Agreement and License, Development and Commercialization Agreement, dated as of May 14, 2021, by and between Brickell Biotech, Inc. and... (Filed With SEC on August 12, 2021)

Amended and Restated Underwriting Agreement, dated July 19, 2021, by and between Brickell Biotech, Inc. and H.C. Wainwright & Co., LLC (Filed With SEC on July 22, 2021)

BRICKELL BIOTECH, INC. 2020 OMNIBUS LONG-TERM INCENTIVE PLAN, AS AMENDED ON APRIL 19, 2021 TABLE OF CONTENTS (Filed With SEC on April 19, 2021)

BRICKELL BIOTECH, INC. EMPLOYEE STOCK PURCHASE PLAN (Filed With SEC on April 19, 2021)

Description of the Registrants Securities Registered Pursuant to Section 12 of the Exchange Act (Filed With SEC on March 9, 2021)

Letter Agreement for Supply of API, dated as of December 8, 2020, by and between Brickell Biotech, Inc. and Kaken Pharmaceutical Co., Ltd (Filed With SEC on March 9, 2021)

Form of Incentive Stock Option Award Agreement under the Brickell Biotech, Inc. 2020 Omnibus Long-Term Incentive Plan (Filed With SEC on March 9, 2021)

Separation Agreement and Release of Claims by and between Brickell Biotech, Inc. and R. Michael Carruthers, effective as of November 30, 2020 (Filed With SEC on November 24, 2020)

Consulting Agreement by and between Brickell Biotech, Inc. and Danforth Advisors LLC, effective as of December 1, 2020 (Filed With SEC on November 24, 2020)

Form of Underwriting Agreement (Filed With SEC on October 22, 2020)

Form of Underwriting Agreement (Filed With SEC on October 19, 2020)

Form of Warrant to Purchase Common Stock (Filed With SEC on October 13, 2020)

Form of Pre-Funded Warrant (Filed With SEC on October 13, 2020)

Form of Warrant Agency Agreement (Filed With SEC on October 13, 2020)

Letter Agreement, dated as of September 3, 2020, by and between Brickell Biotech, Inc. and Kaken Pharmaceutical Co., Ltd (Filed With SEC on October 13, 2020)

First Amended and Restated Employment Agreement, dated September 1, 2020, by and between Brickell Biotech, Inc. and Deepak Chadha (Filed With SEC on October 13, 2020)

Form of Indemnification Agreement by and between the Company and its directors and executive officers (Filed With SEC on August 12, 2020)

Form of Restricted Stock Unit Award Agreement under the Brickell Biotech, Inc. 2020 Omnibus Long-Term Incentive Plan (Filed With SEC on August 12, 2020)

Form of Non-Qualified Stock Option Award Agreement under the Brickell Biotech, Inc. 2020 Omnibus Long-Term Incentive Plan (Filed With SEC on August 12, 2020)

Form of Underwriting Agreement (Filed With SEC on June 17, 2020)

Form of Warrant to Purchase Common Stock (Filed With SEC on June 17, 2020)

Form of Warrant Agency Agreement (Filed With SEC on June 17, 2020)

Form of Underwriting Agreement (Filed With SEC on June 8, 2020)

Form of Warrant to Purchase Common Stock (Filed With SEC on June 8, 2020)

Form of Pre-Funded Warrant (Filed With SEC on June 8, 2020)

Amendment to License, Development and Commercialization Agreement, dated February 24, 2016, by and between Brickell Biotech, Inc. and Kaken Pharmaceutical Co., Ltd (Filed With SEC on June 8, 2020)

Clinical Supply Agreement, dated as of July 30, 2019, by and between Brickell Biotech, Inc. and Kaken Pharmaceutical Co., Ltd., and First Amendment to Clinical Supply Agreement,... (Filed With SEC on June 8, 2020)

Letter Agreement for Supply of API, dated as of April 26, 2020, by and between Brickell Biotech, Inc. and Kaken Pharmaceutical Co., Ltd (Filed With SEC on June 8, 2020)

Consulting Agreement, dated as of December 18, 2017, by and between Brickell Biotech, Inc. and Michael Carruthers; Amendment No. 1 to Consulting Agreement, dated as of March 1,... (Filed With SEC on June 8, 2020)

At Market Issuance Sales Agreement, dated April 14, 2020, by and between the Company and Oppenheimer & Co. Inc (Filed With SEC on April 14, 2020)

Amended and Restated License Agreement, dated February 17, 2020, by and among Brickell Biotech, Inc., Brickell Subsidiary, Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor (Filed With SEC on February 18, 2020)

Settlement Agreement, dated February 17, 2020, by and among Brickell Biotech, Inc., Brickell Subsidiary, Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor (Filed With SEC on February 18, 2020)

Securities Purchase Agreement, dated February 17, 2020, by and between Brickell Biotech, Inc. and Lincoln Park Capital Fund, LLC (schedules omitted) (Filed With SEC on February 18, 2020)

Series A Warrant issued by Brickell Biotech, Inc. to Lincoln Park Capital Fund, LLC (Filed With SEC on February 18, 2020)

Series B Warrant issued by Brickell Biotech, Inc. to Lincoln Park Capital Fund, LLC (Filed With SEC on February 18, 2020)

Purchase Agreement, dated February 17, 2020, by and between Brickell Biotech, Inc. and Lincoln Park Capital Fund, LLC (Filed With SEC on February 18, 2020)

Registration Rights Agreement, dated February 17, 2020, by and between Brickell Biotech, Inc. and Lincoln Park Capital Fund, LLC (Filed With SEC on February 18, 2020)

SETTLEMENT AND TERMINATION AGREEMENT (Filed With SEC on November 25, 2019)

Employment Agreement, dated October 3, 2019, by and between Brickell Biotech, Inc. and Dr. Sanjeev Ahuja (Filed With SEC on October 9, 2019)

Form of Warrant Certificate (Filed With SEC on September 3, 2019)

Funding Agreement, as amended, dated June 2, 2019, by and between Brickell Biotech, Inc. and NovaQuest Co-Investment Fund X, L.P (Filed With SEC on September 3, 2019)

Right of First Negotiation Agreement, as amended, dated March 31, 2015, by and between Brickell Biotech, Inc. and Kaken Pharmaceutical Co., Ltd (Filed With SEC on September 3, 2019)

License Agreement, as amended, dated December 15, 2012, by and among Brickell Biotech, Inc., Bodor Laboratories, Inc. and Nicholas S. Bodor (Filed With SEC on September 3, 2019)

UAB Research Foundation License Agreement, as amended, dated June 26, 2012, by and between Brickell Biotech, Inc. and the UAB Research Foundation (Filed With SEC on September 3, 2019)

License Agreement, dated May 20, 2011, by and between Brickell Biotech, Inc. and the University of Manchester (Filed With SEC on September 3, 2019)

License Agreement, as amended, dated June 6, 2013, by and among Brickell Biotech, Inc, Orca Pharmaceuticals LLC and the New York University (Filed With SEC on September 3, 2019)

Panmira Pharmaceuticals LLC Purchase Agreement, dated January 30, 2015, by and between Brickell Biotech, Inc. and Panmira Pharmaceuticals (Filed With SEC on September 3, 2019)

Boulder Lease Agreement, as amended, dated August 4, 2016, by and between Brickell Biotech, Inc. and BMC Properties, LLC (Filed With SEC on September 3, 2019)

Employment Agreement, dated November 16, 2018, by and between Brickell Biotech, Inc. and Robert Brown (Filed With SEC on September 3, 2019)

Second Amended and Restated Employment Agreement, dated November 27, 2018, by and between Brickell Biotech, Inc. and Andy Sklawer (Filed With SEC on September 3, 2019)

Amended and Restated Employment Agreement, dated August 28, 2019, by and between Brickell Biotech, Inc. and Deepak Chadha (Filed With SEC on September 3, 2019)

Brickell Biotech, Inc. Letter Agreement, dated July 10, 2018 by and between Brickell Biotech Inc. and Jose Breton (Filed With SEC on September 3, 2019)

Employment Agreement, dated July 1, 2019, by and between Brickell Biotech Inc. and David R. McAvoy (Filed With SEC on September 3, 2019)

Employment Agreement, dated August 1, 2019, by and between Brickell Biotech Inc. and Adam Levy (Filed With SEC on September 3, 2019)

Registration Rights Agreement, dated August 31, 2019, by and between Brickell Biotech, Inc. and NovaQuest Co-Investment Fund X, L.P (Filed With SEC on September 3, 2019)

U.S. Security Agreement, dated August 31, 2019, by and between Brickell Biotech, Inc. and NovaQuest Co-Investment Fund X, L.P (Filed With SEC on September 3, 2019)

License, Development and Commercialization Agreement, as amended, dated March 31, 2015, by and between Brickell Biotech, Inc. and Kaken Pharmaceutical Co., Ltd (Filed With SEC on September 3, 2019)

Orca Pharmaceuticals LLC Asset Purchase Agreement, dated June 6, 2013, by and between Brickell Biotech, Inc. and Orca Pharmaceutics (Filed With SEC on September 3, 2019)

Amendment No. 1 to Agreement and Plan of Merger and Reorganization, dated August 20, 2019, by and among the Company, Brickell and Merger Sub (Filed With SEC on August 21, 2019)

Separation Agreement, dated May 21, 2019, by and between the Company and Larry R. Smith, Ph.D (Filed With SEC on July 12, 2019)

Form of Support Agreement, dated June 2, 2019, by and between the Company and each of the parties named in each agreement therein (Filed With SEC on June 3, 2019)

Form of Lock-Up Agreement, dated June 2, 2019, by each of the parties named in each agreement therein (Filed With SEC on June 3, 2019)

Agreement and Plan of Merger and Reorganization, dated June 2, 2019, by and among the Company, Brickell Biotech and Merger Sub (Filed With SEC on June 3, 2019)

FIRST AMENDMENT TO LEASE (Filed With SEC on August 9, 2016)

STOCK PURCHASE AGREEMENT (Filed With SEC on August 9, 2016)

AMENDMENT No.1 (Filed With SEC on October 30, 2015)

LICENSE AGREEMENT (Filed With SEC on May 8, 2015)

SEVERANCE AGREEMENT (Filed With SEC on February 26, 2015)

Vical Incorporated Non-Employee Director Compensation Policy (Filed With SEC on May 2, 2014)

10390 Pacific Center Court, San Diego, CA92121-43408586461100, FAX: 8586461150www.vical.com (Filed With SEC on August 22, 2013)

CONSULTING AGREEMENT SIXTH AMENDMENT (Filed With SEC on August 1, 2013)

EXHIBIT A OPTION TERMS (Filed With SEC on March 15, 2013)

CONSULTING AGREEMENT FIFTH AMENDMENT (Filed With SEC on February 15, 2013)

VICAL INCORPORATED Common Stock ($0.01 par value per share) AT-THE-MARKET EQUITY OFFERING SALES AGREEMENT (Filed With SEC on November 7, 2012)

CONSULTING AGREEMENT FOURTH AMENDMENT (Filed With SEC on August 8, 2012)

1ST AMENDMENT toU.S. LICENSE AGREEMENT BETWEEN VICAL INCORPORATED AND ASTELLAS PHARMA INC. (Filed With SEC on August 8, 2012)

1ST AMENDMENT toEx-U.S. LICENSE AGREEMENT BETWEEN VICAL INCORPORATED AND ASTELLAS PHARMA INC. (Filed With SEC on August 8, 2012)

1ST AMENDMENT to SUPPLY AND SERVICES AGREEMENT BETWEEN VICAL INCORPORATED AND ASTELLAS PHARMA INC. (Filed With SEC on August 8, 2012)

Vical Incorporated Non-Employee Director Compensation Policy (Filed With SEC on May 2, 2012)

CONSULTING AGREEMENT THIRD AMENDMENT (Filed With SEC on March 15, 2012)

13,333,334 Shares VICAL INCORPORATED Common Stock ($0.01 par value per Share) UNDERWRITING AGREEMENT (Filed With SEC on January 9, 2012)

U.S. LICENSE AGREEMENT (Filed With SEC on November 4, 2011)

EX-U.S. LICENSE AGREEMENT (Filed With SEC on November 4, 2011)

SUPPLY AND SERVICES AGREEMENT (Filed With SEC on November 4, 2011)

EXCLUSIVE LICENSE AGREEMENT (Filed With SEC on November 4, 2011)

CONSULTING AGREEMENT SECOND AMENDMENT (Filed With SEC on August 3, 2011)

CONSULTING AGREEMENT FIRST AMENDMENT (Filed With SEC on March 4, 2011)

CONSULTING AGREEMENT (Filed With SEC on November 9, 2010)

15,000,000 Shares VICAL INCORPORATED Common Stock ($0.01 par value per Share) UNDERWRITING AGREEMENT (Filed With SEC on September 24, 2010)

AMENDED AND RESTATED STOCK INCENTIVE PLAN OF VICAL INCORPORATED (Filed With SEC on August 6, 2010)

Vical Incorporated Non-Employee Director Compensation Policy (Filed With SEC on May 7, 2010)

Vical Incorporated Non-Employee DirectorCompensation Policy (Filed With SEC on February 25, 2010)

VICAL INCORPORATED DELAYED ISSUANCE STOCK PURCHASE GRANT NOTICE (AMENDED AND RESTATED STOCK INCENTIVE PLAN) (Filed With SEC on February 25, 2010)

COMMON STOCK PURCHASEAGREEMENT Dated as of January 8, 2010 by and between VICAL INCORPORATED and AZIMUTH OPPORTUNITY LTD. TABLE OF CONTENTS (Filed With SEC on January 8, 2010)

Rodman & Renshaw, LLC 1251 Avenue of the Americas, 20th Floor, New York, NY 10020 (Filed With SEC on May 22, 2009)

COMMON STOCK PURCHASE WARRANT VICAL INCORPORATED (Filed With SEC on May 22, 2009)

AMENDED AND RESTATED STOCK INCENTIVE PLAN OF VICAL INCORPORATED (Filed With SEC on May 8, 2009)

VICAL INCORPORATED DELAYED ISSUANCESTOCK PURCHASE ELECTION AGREEMENT (Filed With SEC on March 3, 2009)

FIRST AMENDMENT TO (Filed With SEC on November 9, 2007)

VICAL INCORPORATED 10390 Pacific Center Court (Filed With SEC on November 9, 2006)

MASTER SECURITY AGREEMENT No. 6081123 (Filed With SEC on August 25, 2006)

VICAL INCORPORATED 10390 Pacific Center Court (Filed With SEC on August 7, 2006)

RESEARCH AND DEVELOPMENT AGREEMENT (Filed With SEC on August 7, 2006)

STOCK PURCHASE AGREEMENT (Filed With SEC on August 7, 2006)

Amendment to License Agreement (Filed With SEC on May 8, 2006)

4,704,000 Shares (Filed With SEC on October 12, 2005)

FIFTH AMENDMENT TO RESEARCHCOLLABORATION AND LICENSE AGREEMENT DATED MAY 31, 1991 (Filed With SEC on October 12, 2005)

LICENSE AGREEMENT (Filed With SEC on August 8, 2005)

VICAL INCORPORATED 10390 Pacific Center Court San Diego, CA 92121-4340 April 15, 2005 (Filed With SEC on May 10, 2005)

VICAL INCORPORATED DELAYED ISSUANCE STOCK PURCHASE GRANT NOTICE (Filed With SEC on March 15, 2005)

THIRD AMENDMENT TORESEARCH COLLABORATION AND LICENSE AGREEMENT DATED MAY 31, 1991 (Filed With SEC on August 9, 2004)

AMENDMENT TO LICENSE AGREEMENT (Filed With SEC on August 9, 2004)

SECURITYAGREEMENT (Securities) Dated as of March 19, 2004 (Filed With SEC on May 10, 2004)

3,379,000 Shares VICAL INCORPORATED (Filed With SEC on March 24, 2004)

VICAL INCORPORATED 10390 Pacific Center Court San Diego, CA 92121-4340 March 15,2004 (Filed With SEC on March 24, 2004)

SOLICITATION (Filed With SEC on March 11, 2004)

FOURTHAMENDMENT TO RESEARCH COLLABORATION AND LICENSE AGREEMENT DATED MAY 31,1991 (Filed With SEC on November 14, 2003)

INDEMNITY AGREEMENT (Filed With SEC on March 31, 2003)

to the Research, Option and LicenseAgreement dated September 29, 1994 (Filed With SEC on March 31, 2003)

VICAL INCORPORATED 9373 Towne Centre Drive Suite 100 San Diego, CA 92121 March 10, 2003 (Filed With SEC on March 31, 2003)

Category

Industry

Companies

Contracts

VICAL INC Contracts & Agreements